Member Info for Mikey279

Just let the fundamentals and SP do the talking.... would not be surprised to see the £s over the next few weeks

IMO

Not unreasonable, but the 2 key things here are:

No one would be chancing a 55% routine annual test if there's a 90%+ one out there, private or not. I know which one I'm going for.

2) The market doesn't 'wait' until rollout to value a company, it's forward looking - if it can be worth multiple billions at some point it'll place a value on that

3) There's been minimal PR currently, but wait until word spreads

Will be the biggest success story on AIM

All IMO

Not even the best RNS of the year, probably in a decade..... 10x from would still be dirt cheap IMO

I've seen anywhere from $300-$1000 per test

25m from USA, 5m from UK, other countries to follow?

EpiSwitch - check out the rest of the pipeline

Just do the Math, this is unheard of in the LSE

All IMO

Going to try a less rampy projection:

The numbers quoted are around 25m in the USA and 5m in the UK tested annually

Assuming we will capture 80% of the uk considering it’s been 10 years work with NHS collab

That gives us 4m, we also lead science guidelines in global healthcare, say just 10% of the USA testing at 2.5m

Gives us 6.5m per annum, an inferior test has been quoted at 300$ earlier assuming profits are at 1/3 that’s $100 per piece

Giving us $650m or £500m in profit per annum, apply a low P/E of 3

Gives us £1.5bn/250m shares (we will need a raise at some point next year probably)

Which is £6 per share

This opportunity is unheard of, no wonder the directors are in heavy at much higher prices and this reached £2+ at one point

This is just two countries and one arm of episwitch, which o wouldn’t be surprised to see it go to big pharma for several billion

All IMO

Trust me when I say 10bag from here is selling it way short for what we have on offer, do the numbers yourself 30m per annum for two countries only, a monopoly of the market, apply profit and P/E

IMO

You’ll see how insignificant this is when we move 20-30p in a day

Best rns in years now

IMO

Keep saying it but should be in the £s... the £300k buy at day highs at 39.9p wasn't for nothing lol

IMO

This share possibly has the biggest upside of any share in the market if you consider the numbers vs current mcap, it could be £2 (ATHs) and no one would bat an eyelid

All IMO

All IMO

30m tests per year at £750….. £22.5bn

Lol there’s nothing better out there is there ?

£100 per share ? Biggest upside to any company on the LSE if all goes to plan

All IMO

Just imagine the partnerships/resellers and manufacturers buzzing the phone for this….

Can easily be in the billion mcap and no one would bat an eye

All IMO

Are you an idiot slacker?

Mass accurate testing reducing need of biopsy means earlier detection means higher likelihood of successful treatment

It’s ready for launch why you still talking about approval? Widespread use will come fast once guidelines are in place

Data from the PROSTAGRAM NHS study, published in Cancers, a high-impact, peer-reviewed journal in February 2023, showed that PSE demonstrated compelling results of 93% positive predictive value, 95% negative predictive value and overall accuracy of 94%. The Company experienced an unprecedented level of interest in the test following the announcement of the publication of these results, both from doctors and in the mainstream media. In response, the Company has moved quickly to expedite development and commercial launch of the test.

The Company's PSE test will offer a rapid, minimally invasive, accurate test with significant potential as a screening diagnostic and large addressable markets. In the US there are approximately 47 million men aged between 50 and 74, with 25 million PSA tests performed annually (2021 figures). There are approximately 10 million men in the same age bracket in the UK.

Calling it now Episwitch goes for several billion

All IMO

Think about EUA NCYT and what it meant to have a world beating asset, the sp got stuck and drifted at times too but eventually did nearly 100x from low ,unfortunately for them macro circumstances fizzled it out but this can possibly last a lifetime and the amount of lives we save is priceless

Who cares about day to day buys and sells, the fundamental always rerates, they funded recently and literally have a goldmine ready for sale. The biggest risers always backrest and consolidate. This will be in the £s this side of the year IMO

Patience will pay

NCYT, EUA, GGP......100 baggers are once in a blue moon

OBD is next IMO

PSA got approved in the 1980s... the fact that there's been nothing more reliable in use since then speaks volumes, they can charge what they like after 10 years+ of work and they own the patents

Imagine 30,000,000 x £1000

My calculator just broke

The SP will break too, once people start looking at what we have here rather than the buys/sells

All IMO

From previous RNS:

Following the publication of the results involving OBD's technology in the multi-disciplinary NHS PROSTAGRAM study using blood to detect prostate cancer on 6 February 2023, there has been unprecedented levels of interest in and demand for access to the PSE test.

Is this a monopoly

Repost from a previous poster

It's always difficult to get a true market value, but if we look at what we know

Analysts at Shore Capital said: “There are approximately 47 million men in the relevant 50-80 age range in the key US market and 25 million PSA tests per year, and a further 10 million men in the UK. The medical need for an improved test is clear.

I saw a video posted on here where the company stated the product would cost around £100 each.

57,000,000 x £100 = 5.7 billion.

Divide that by the share issue you're looking at £41 a share. Admittedly this is a very simple and quite frankly overly optimistic analysis, but it gives us some indication.

Wouldn't say 57m but assuming 50% get tested as per the numbers, its closer to 30m, this is just for USA and UK only

Assuming a small margin of even £20 thats £600m on a conservative PE of 5, thats £3bn/250m (going to allow for some ramp up dilution although we've just raised recently) shares in issue , thats £12 per share upside on a conservative basis.

The less conservative side you're looking at extraordinary numbers.

Probably the most undervalued share in the entire market right now and a gamechanger for men's health.

Not to mention this is only ONE arm of the platform.

Enjoy the re-rate, wouldn't be surprised at all to see a few £s this side of the year

All IMO DYOR

One to just let the fundamentals do it’s job, you get these shares once every 10 years or so IMO

Sit back and relax IMO

Think about how many lives can be saved now